Best peptides for sexual health
Peptides that support libido, erectile function, and sexual performance through neurological and vascular pathways.
What to know
PT-141 (bremelanotide/Vyleesi) is FDA-approved for hypoactive sexual desire disorder in women and used off-label for male sexual dysfunction. It works through melanocortin receptors in the brain — a fundamentally different mechanism than PDE5 inhibitors (Viagra/Cialis). Nausea is the main side effect. GH peptides indirectly support sexual health through improved hormone balance and energy. Kisspeptin is emerging as a research peptide for sexual arousal.
Recommended peptides
PT-141
other
PT-141 (Bremelanotide) is FDA-approved for hypoactive sexual desire disorder in women. It works through the melanocortin system rather than the vascular system like Viagra.
Kisspeptin
other
Kisspeptin is a neuropeptide that triggers the release of GnRH, playing a key role in puberty onset and reproductive hormone regulation.
Ipamorelin
gh-secretagogue
Ipamorelin is a synthetic pentapeptide and growth hormone releasing peptide (GHRP) that stimulates the pituitary gland to secrete growth hormone through selective activation of the ghrelin receptor (GHS-R1a). Developed in the late 1990s by Novo Nordisk, it was characterized in a landmark 1999 study as the first GHRP to release GH with absolute selectivity, meaning it does not significantly elevate cortisol, prolactin, ACTH, FSH, or LH at pharmacological doses (PMID: 10580762). This hormonal selectivity distinguishes it from older GHRPs like GHRP-2 and GHRP-6, which produce meaningful cortisol and prolactin elevations that can complicate long-term use. Ipamorelin is most commonly combined with CJC-1295 (a GHRH analog) to produce synergistic GH release through dual-pathway stimulation. The two peptides act on different receptors and when administered together produce GH output substantially greater than either compound alone. This combination has become one of the most widely used peptide protocols in anti-aging medicine and performance-oriented use. Ipamorelin was placed on the FDA Category 2 bulk drug substance list in 2023, restricting compounding pharmacy production, though regulatory status remained in flux following a February 2026 announcement from HHS regarding potential reinstatement of certain peptides.
CJC-1295
gh-secretagogue
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered to dramatically extend the half-life of natural GHRH signaling. Developed by ConjuChem Biotechnologies in the early 2000s, it exists in two distinct forms that are frequently confused: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, also known as Modified GRF (1-29) or mod GRF 1-29. Understanding this distinction is essential — they share a name but have fundamentally different pharmacokinetic profiles. The DAC version uses a reactive chemical group called maleimidopropionic acid (MPA) that forms a covalent bond with serum albumin after injection. This albumin binding shields the peptide from enzymatic degradation and extends its half-life from minutes to 5.8-8.1 days (PMID: 16352683). Native GHRH has a half-life of approximately 7 minutes, making this roughly a 1,000-fold improvement in duration. The landmark Teichman et al. trial demonstrated that a single CJC-1295 DAC injection produced dose-dependent GH increases of 2- to 10-fold sustained for 6 or more days, with IGF-I levels rising 1.5- to 3-fold for 9-11 days (PMID: 16352683). The no-DAC version (mod GRF 1-29) has four amino acid substitutions at positions 2, 8, 15, and 27 that improve stability against dipeptidylpeptidase-IV (DPP-IV) cleavage compared to native GHRH, but without albumin binding, its half-life is approximately 30 minutes. This shorter duration preserves the natural pulsatile pattern of GH release — the body's own rhythm of GH spikes followed by quiet periods — which many researchers and clinicians consider preferable to the continuous elevation produced by the DAC form. A critical finding from the Ionescu and Frohman study confirmed that even the DAC version preserves GH pulsatility: basal GH levels increased 7.5-fold, but GH pulse frequency and magnitude remained unchanged, meaning the pituitary's natural secretory rhythm was maintained rather than overridden (PMID: 17018654). This is a meaningful safety distinction from exogenous HGH, which produces flat, supraphysiologic GH levels that suppress the body's own production. CJC-1295 has never been FDA-approved for any indication. A Phase II clinical trial of the DAC version for HIV-associated lipodystrophy was halted in July 2006 after a participant died hours after his 11th injection at an Argentine study site. The cause of death was confirmed as acute myocardial infarction. The attending physician attributed the MI to pre-existing asymptomatic coronary artery disease unrelated to CJC-1295 treatment. The study enrolled 192 HIV-positive participants with significant cardiovascular risk factors, and ConjuChem eventually went bankrupt without completing the trial. The FDA flagged cardiac concerns when reviewing CJC-1295 during the 2024 PCAC process, indicating the regulatory signal was not fully dismissed. This remains the only reported fatality associated with CJC-1295. CJC-1295 was placed on the FDA Category 2 bulk drug substance list in late 2023, effectively prohibiting compounding pharmacies from preparing it. In September 2024, the FDA referred it to the Pharmacy Compounding Advisory Committee (PCAC), which flagged cardiac side effects and immunogenicity concerns. On February 27, 2026, HHS Secretary RFK Jr. announced that approximately 14 of 19 restricted peptides would return to legal compounding status, though the specific list has not been officially published and CJC-1295's inclusion remains uncertain due to its cardiac flagging. CJC-1295 is prohibited at all times by WADA under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.
Get the Sexual Health cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Recommended stacks
Explore other goals
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026